Sustainable utilization of bovine adipose tissue derivatives as robust antimicrobial agents against Methicillin-resistant Staphylococcus aureus
Alcici MAI., Abdelhaleem SW., Fahim KM., Saleh NM., Farag HS.
Animal Study, published in BMC Microbiol (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- BMC Microbiol (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 39881215
- PMCID
- PMC11776113
- DOI
- 10.1186/s12866-025-03747-5
Abstract (original English)
Background The excessive use of antibiotics is a major contributor to the global issue of antimicrobial resistance (AMR), a significant threat to human and animal health. Hence, assessing new strategies for managing Multi-Drug Resistant (MDR) microorganisms is vital. In this study, the use of mechanically isolated mature adipose cells (MIMACs) and their lysate (Adipolysate) as a new sustainable antimicrobial agent was assessed against Methicillin-resistant Staphylococcus aureus (MRSA). Conclusions The minimum volume of MIMACs achieved complete bacterial inhibition (Minimum Lethal volume) was 75 µl and 100 µl for bacterial concentration of 10 10 and 10 12 cfu/ml, respectively. Direct bacterial membrane attachment and intracellular capture was visualized under light and electron microscopy. Adipolysate was characterized via GC-MS, the fatty acid profile demonstrated several components with known antimicrobial properties. The tested Adipolysate revealed inhibition zone of diameter 25.33 ± 0.88 mm against the tested S. aureus strain, compared with the inhibition zone of Vancomycin (24.0 ± 0.00 mm) and Erythromycin (30.0 ± 0.00). The study revealed the potential effects of MIMACs and Adipolysate as sustainable, natural, and robust antimicrobial agents. However, these preliminary results will be further investigated to understand the mechanism of action and explore possible applicati
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.